-
Incyte to Present at Upcoming Investor Conferences
Incyte to Present at Upcoming Investor Conferences
Share
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November:
- Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology (INI) Conference on Tuesday, November 7, 2023 at 1:10 pm (EST)
- Evercore ISI 6th Annual HealthCONx Conference on Thursday, November 30, 2023 at 12:30 pm (EST)
The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Contacts
Incyte
Media
media@incyte.com
Investors
ir@incyte.com
Incyte
More News From Incyte
Incyte Announces Executive Leadership Appointments
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Executive Leadership Appointments...
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting...
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for First-Line Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)...
